Kornimate/medical-research-clean huggingface dataset:
starlight therapy in palliative care

Conditions: Symptom Management

Summary: starlight therapy™ has been shown to help alleviate end-of-life symptoms in palliative care patients and reduce the need for prn or "as needed" medications. this study will investigate the efficacy of this intervention on the symptom of anxiety using a mixed-method analysis. the primary investigator hypothesizes that any anti-anxiolytic effects could be caused by the intrinsically photosensitive retinal ganglion cell neural pathway to the amygdala.

starlight therapy has been shown (see citation) to help alleviate end-of-life symptoms in palliative care patients and reduce the need for prn or "as needed" medications. this study will investigate the efficacy of this intervention using a mixed-method analysis. starlight therapy will be offered to patients with unpleasant end-of-life symptoms such as dyspnea, agitation, anxiety, restlessness and insomnia. the effect the starlight therapy has in helping alleviate these symptoms will be measured using the esas (edmonton symptom assessment system) questionnaire at baseline and following a predetermined period of time of starlight therapy. 10 starlight projectors have been purchased for the unit where the study will take place: the inpatient palliative care unit 7a, victoria general hospital, centennial building. the funding was acquired by a comfort \& care grant from the qeii foundation. the results will be compiled and analyzed in a research paper "concerning the efficacy and underlying mechanism of starlight therapy as a non-pharmacological nursing intervention for palliative care patients".

Eligibility criteria:
inclusion criteria: 1. esas indicates at least one of the following symptoms: * insomnia * anxiety * restlessness * dyspnea * pain exclusion criteria: 1. clinical diagnosis of blindness 2. esas does not include any of the flowing symptoms: * insomnia * anxiety * restlessness * dyspnea * pain

Keywords: palliative starlight end-of-life symptoms non-pharmacological
the efficacy and safety of new herbal formula (kbmsi-2) in the treatment of erectile dysfunction

Conditions: Erectile Dysfunction

Summary: background: kbmsi-2, which is the herbal formular consisted of ginseng radix rubra, dioscorea tenuipes, cornus officinalis sieb. et zucc, lycium chinese mill, curcuma logna linn, honey, improved the erectile function by preserving the smooth muscle content and inhibiting the fibrosis of the corpus cavernosum in stz-induced diabetic rat model. in this study, the researchers investigated the efficacy and safety of the herbal formula (kbmsi-2) in the treatment of ed. material and methods: patients were instructed to take investigational products (kbmsi-2 6g or placebo) twice a day for 8 weeks at least 1 hour after food intake. the primary efficacy variable was the change in the ef domain scores of the iief questionnaire from baseline. secondary efficacy measures included change in all domain scores of the iief from baseline, change in question 2 and 3 of the sep2,3, from baseline.


Eligibility criteria:
inclusion criteria were as follows: * men with history of ed for at least 6 months according to the national institutes of health (nih) consensus statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance); * erectile function (ef) domain scores of the international index of erectile function (iief) questionnaire ≤ 25; * age range between 19 and 40 years old; * patients were required to be involved in a stable, monogamous relationship with a female sexual partner and having failed \>50% of at least four sexual attempts during the run-in period. exclusion criteria were as follows: * men with the following conditions were excluded from the study: * penile anatomical defects, * spinal cord injury, * radical prostatectomy, * and radical pelvic surgery; * a primary diagnosis of another sexual disorder; * uncontrolled dm (hba1c\> 12%); * serum creatinine\>2.5mg/dl; * major uncontrolled psychiatric disorder; * history of major hematological, renal, or hepatic abnormalities; * recent (within the previous 6 months) history of cardiovascular disease, stroke or myocardial infarction, cardiac failure, unstable angina, life-threatening arrhythmia and a history of alcoholism or substance abuse. * patients having taken pde5 inhibitors and testosterone replacement therapy within 2 weeks were excluded in the study. concomitant use of ed treatment was forbidden.
intestinal metaplasia cohort for gastric cancer prediction

Conditions: Intestinal Metaplasia of Gastric Mucosa

Summary: in this study, we aim to establish a prospective cohort of patients with endoscopically and histologically confirmed intestinal metaplasia, collect gastric mucosal tissue samples from this cohort, and follow the development of gastric cancer over time.

patients visiting seoul national university hospital, who have previously received an incidental diagnosis of intestinal metaplasia during a prior gastroscopy examination, will be considered as potential candidates for this study. upon obtaining their informed consent to participate, the initial endoscopy procedure will involve the collection of biopsies to ensure an accurate histological diagnosis of intestinal metaplasia. these biopsies will be taken from the antrum and body of the stomach, according to the protocol of the updated sydney system, to pathologically diagnose the extent and severity of intestinal metaplasia. one to two pieces of tissue remaining from this diagnostic process will be retained for future analysis. subsequently, patients will be followed up on an outpatient basis to track the development of gastric cancer through routine screening endoscopies. in cases where patients develop gastric cancer, a comparative analysis will be conducted with those who do not develop gastric cancer, to determine the differences in expression of markers in the gastric mucosal tissue that was collected during the initial endoscopy. our ultimate aim is to identify potential biomarkers that may serve as predictive indicators for the development of gastric cancer in patients with a preexisting diagnosis of intestinal metaplasia.

Eligibility criteria:
inclusion criteria: * patients who visit seoul national university hospital * patients who have been visually diagnosed with intestinal metaplasia at a prior exam exclusion criteria: * patients who have been previously diagnosed with gastric cancer or adenoma * patients who have previously received gastrectomy
ultrasound in evaluation of preoperative fluid management of hip fracture surgery patients

Conditions: Lung Edema; Hip Fractures

Summary: goal directed fluid therapy is a new standard surgical procedure which is successful in patients undergoing hip revision arthroplasty, there has been a reduction of postoperative complications, most importantly surgery with a decrease inbleeding, as well as in hospital and intensive care stays it is related. the aim of this study is to evaluate effectiveness of pulmonary ultrasound score and vena cava collapse index measurements in the patients undergoing hip surgery under spinal anesthesia and relation with peroperative fluid management.

patients who will undergo hip surgery under spinal anesthesia using the closed envelope method it will be randomized and divided into 2 groups. 1.the inferior vena cava collapse index ivc ci and lung ultrasound score (lus) measurements and goal directed fluid therapy will be done 2. group applying zero balance liquid therapy to patients with conventional methods is planned. 1. patients in the group will be started with fluid replasment at an hourly rate of 2ml/kg/h and with ultrasound measurement the infused fluid will be evaluated and regulated. 2. crystalloid liquid infusion at a rate of 2ml/kg/hour will be administered to the patients in the group additional fluid replacement will be decided by monitoring bleeding and urinary output, zero balance is aimed at patients. both groups were treated with spinal anesthesia in the postoperative period 120. minute ivc ci and the lus score value will be checked. if the ci is below 50% and the lus score is below 15, fluid management will be considered as successful.

Eligibility criteria:
inclusion criteria: * patients over the age of 65 who will undergo hip surgery * asa i-ii-iii patients exclusion criteria: * patients under the age of 65 * patients with asa iv-v * patients with bmi\>above 35 * patients with an lus score of 15 and above * patients who have not undergone spinal anesthesia
effectiveness of preoperative tour in simulation operating theater in reducing preoperative anxiety in children

Conditions: Anxiety

Summary: this study conducted to evaluate the effectiveness of preoperative tour to simulation operating theater on reducing children's and parents' preoperative anxiety. half of the participant were taken in a tour to a simulation operating theater before the day of operation and the other half were given the standard of care.

the investigators examined the effectiveness of a preoperative tour to a simulation operating theater guided by an expert anesthesia technologist on reducing the preoperative anxiety levels for children who were scheduled for elective day case procedures under general anesthesia, and their parents' anxiety levels through a 10-months randomized controlled trial at tertiary medical center in riyadh-saudi arabia, and confirmed that children and parents who received the intervention had significantly lower preoperative anxiety levels than controlled children and parents. given that, the results showed critical levels of preoperative anxiety among school age children, and that preoperative tour to simulation operating theater as a child-friendly maneuver is directly applicable and could be considered for children scheduled for day-case procedures under general anesthesia.

Eligibility criteria:
inclusion criteria: * children who were scheduled for elective day-case procedures under general anesthesia at kfmc. * class 1 or 2 according to the american society of anesthesiology physical status. exclusion criteria: * diagnosed as having mental or psychological disorders.
efficacy and safety study of dha-o in adults with hypertriglyceridemia

Conditions: Hypertriglyceridemia

Summary: the purpose of this study is to investigate the efficacy and safety of dha-o to lower elevated triglyceride levels in healthy adults with hypertriglyceridemia.


Eligibility criteria:
inclusion criteria: * ages 18-79 * fasting tg levels, 150-499 mg/dl * baseline dha intake \<200mg/d * active and in good health exclusion criteria: * recent diagnosis of chd or history of revascularization within 6mos of study * use of lipid altering medications (other than stable statins) * use of anticoagulants * use of omega-3 products within 4 weeks of screening * serum ast/alt \>1.5x uln and/or creatinine \>1.5 mg/dl at screening * lipid altering foods or supplements * women who are pregnant or of childbearing potential not using adequate birth control * current use or history of drug or alcohol abuse * inability to swallow capsules

Keywords: omega-3 dha triglycerides lipids cardiovascular hypertriglyceridemia
randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable local advanced gastric cancer

Conditions: Advanced Gastric Cancer

Summary: gastric cancer is the leading cause of death from a intestinal tract cancer in china.in most cases, the high death rate is due to tumor that has spread beyond the gastric cancer at the time of diagnosis. in china, the standard chemotherapy for the initial treatment of gastric cancer is a combination of a platinum analogue with 5-fu.with modern surgical interventions and contemporary chemotherapy, most patients attain better clinical remission.the majority of them, however, will eventually have a relapse and die of the disease. the peritoneal cavity is the principal site of disease in gastric cancer.although the intensity of intravenous chemotherapy is limited mainly by myelotoxicity, several active drugs can be administered directly into the peritoneal cavity. the rationale for intraperitoneal therapy in gastric cancer is that the peritoneum, the predominant site of tumor, receives sustained exposure to high concentrations of antitumor agents while normal tissues, such as the bone marrow, are relatively spared. the investigators conducted this trial to investigate the efficacy and safety of intraperitoneal chemotherapy in advanced gastric cancer.

to investigate efficacy and safety of intraperitoneal chemotherapy as part of adjuvant treatment for advanced gastric cancer.

Eligibility criteria:
inclusion criteria: disease characteristics * histologically confirmed primary adenocarcinoma of the stomach * 3-4weeks after radical operation for gastric cancer * stage of the gastric cancer was t3-4nxm0 patient characteristics: * age: 18 - 70years old life expectancy: * longer than 3 months hematopoietic: * granulocyte count at least 1,500/mm3 * platelet count at least 100,000/mm3 * hemoglobin at least 80\*10\^12/mm3 hepatic: - ast no greater than 2.5 times uln renal: * creatinine no greater than 1.5 times uln other: * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * not specified chemotherapy: * prior chemotherapy and radiotherapy were not allowed * no other concurrent chemotherapy radiotherapy: * locally radiotherapy for local disease of advanced gastric cancer during adjuvant treatment was allowed surgery: * see disease characteristics * prior surgery for gastric cancer was necessary exclusion criteria: * haven't recovery from operation or complication of operation * with the following risk factors: uncontrolled or severe cardiovascular disease (e.g., myocardial infarction within the past 6 months, congestive heart failure treated with medications, or uncontrolled hypertension) * pregnant or nursing * other currently active malignancy except nonmelanoma skin cancer * uncontrolled or severe bleeding,diarrhea,intestinal obstruction,adhesion of intestine * metastasis before enrollment * received other chemotherapy or radiotherapy after operation

Keywords: intraperitoneal chemotherapy cisplatin fluorouracil advanced gastric cancer
complete mesocolic excision in comparison with conventional surgery for the right colon cancer

Conditions: Colon Cancer

Summary: an italian randomized controlled trial parallel-group in patients with a malignant tumor of the right or proximal transverse colon requiring right hemicolectomy.

this study aims to compare the complete mesocolic excision with central vascular ligation (cme+cvl) with the standard (non-cme) right hemicolectomy in patients with right or proximal transverse colon cancer stage ii-iv(ajcc 8th edition) to determine the short and long term outcomes in terms of disease-free survival (dfs) as a primary endpoint, and safety, oncologic outcomes, quality of surgery and quality of life (qol) as secondary endpoints. eligible patients will be randomized with a 1:1 ratio between cme + cvl vs standard non-cme right colectomy. the randomization sequence will be generated centrally by a computed algorithm and kept concealed to investigators. the right colectomy with cme + cvl includes the removal of the accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia. despite the surgical approach and the type of procedure adopted, the operation should be strictly conducted following the general rules for colorectal oncologic resection, particularly as concerns proximal and distal margins length and lymph node retrieval. all surgical approaches (open, laparoscopic, or robotic) will be allowed while the type of anastomosis performed and drain placement will be up to the surgeon's discretion. demographic, baseline, perioperative and postoperative characteristics will be analyzed as well. the study expected to last six and a half years, of which one and a half years for recruiting 416 patients, 208 each arm, with five years of follow-up. patients will be followed up at 1, 4, 12, 24, 36, and 60 months postoperatively.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists(asa) grade i-iii. * right colon cancer (\*the right-sided location of the cancer is defined as the location from the caecum up to the proximal third of the transverse colon), preoperative assessment of tumor stage t2-t4a, any n or t any n+ according to the national comprehensive cancer network(nccn) clinical practice guidelines in oncology: colon cancer version 2.2015); no distant metastasis. * informed consent exclusion criteria: * age \> 85 years old. * t1, n0 * t4b, any n * bmi \> 30. * metastatic disease (abdominal and chest ct scan will be mandatory to exclude distant metastasis.) * american society of anesthesiologists(asa) grade iv. * history of cancer in recent 5 years. * need for emergency surgery. * infectious disease requiring treatment. * pregnancy. * use of systemic steroids. * no history of familial adenomatous polyposis, ulcerative colitis or crohn's disease.

Keywords: colon cancer right colon cancer complete mesocolic excision cme right hemicolectomy right colectomy
study evaluating temsirolimus in advanced stage squamous cell carcinoma of the head & neck

Conditions: Squamous Cell Carcinoma

Summary: this is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. the primary objective of this study is to identify biomarkers of temsirolimus activity.


Eligibility criteria:
inclusion criteria: * subjects with newly diagnosed, advanced stage, head and neck squamous cell carcinoma of the oral cavity, oral pharynx, hypopharynx or larynx. * subjects willing to undergo tumor biopsies. * eastern cooperative oncology group (ecog) performance status of 0-1. * age \>/= 18 years. exclusion criteria: * subjects receiving anticoagulation therapy. * presence of unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia. * prior cancer therapy (chemotherapy, hormonal therapy, radiotherapy, immunotherapy) or investigational agent for their head and neck cancer.

Keywords: carcinoma head neck
effect of thoracic manual therapy in hemiplegic patients

Conditions: Stroke

Summary: neurological problems both lead to many respiratory problems primarily and events secondary to neurological diseases or symptoms can be the cause of respiratory failure. the addition of respiratory failure will adversely affect the course of the neurological picture, making treatment more difficult. the cardiopulmonary functions of hemiplegia patients decrease due to the decrease in the expansion of the thoracic part on the hemiplegic side and insufficient respiratory muscles. in addition, common symptoms in stroke patients, including limited use of ankylosis and muscle movements, cause oxygen deficiency and increased metabolic demands. after stroke, thoracic expansion is reduced upon paralysis of the diaphragm and respiratory muscles. continuation of this condition can lead to muscle fibrosis. as a result, the level of thoracic expansion decreases during breathing. a decrease in thoracic spine mobility correlates with a decrease in forced vital capacity (fvc) and forced expiratory volume in the first second (fev1). the increase in the rigidity of the chest wall affects the ventilator pumping mechanism, reducing the level of rigidity (increasing the mobility of the chest wall) is recommended as a way to improve lung function.


Eligibility criteria:
inclusion criteria: * being between 45-65 years old * stage 4-6 according to brunnstrom * according to modified ashworth, the upper extremity is at most two values * sufficient to answer the level of consciousness survey * no smoking * no hearing or vision loss exclusion criteria: * not being able to read and write * having cognitive impairment * hearing difficulties and vision loss * having any acute pain * acute bronchitis

Keywords: pulmonary function manual therapy respiratory function test
ultrasound-guided vs. blinded dry needling for piriformis syndrome

Conditions: Piriformis Syndrome

Summary: this randomized controlled trial aims to compare the effectiveness of ultrasound-guided versus blinded dry needling for the treatment of piriformis syndrome.

this randomized controlled trial aims to compare the efficacy of ultrasound-guided versus blinded dry needling for the treatment of piriformis syndrome. patients in both groups will receive three weekly sessions of dry needling performed by a single experienced physiatrist. the intervention will involve inserting a sterile acupuncture needle into the trigger points of the piriformis muscle and manipulating the needle to elicit a twitch response. patients in the ultrasound-guided group will receive dry needling under real-time ultrasound guidance, while patients in the blinded group will receive dry needling without ultrasound guidance. patients will be assessed before treatment, after treatment, after the third week, and after three months.

Eligibility criteria:
inclusion criteria: * male or female patients aged 18-65 years. * clinical diagnosis of piriformis syndrome based on the following criteria: buttock pain, radiating pain to the posterior thigh, and tenderness over the piriformis muscle. * pain intensity of at least 4 out of 10 on a visual analog scale (vas). * willingness to comply with the study protocol and provide informed consent. exclusion criteria: * previous surgery or injection therapy for piriformis syndrome. * contraindications to dry needling, such as bleeding disorders or skin infections. * pregnancy or breastfeeding. * history of neurological disorders, such as sciatica, radiculopathy, or neuropathy. * history of serious psychiatric illness or substance abuse. * inability to complete the study questionnaires or follow-up assessments.